<DOC>
	<DOCNO>NCT02315534</DOCNO>
	<brief_summary>This open label , multi-center , phase 1 safety run-in phase 2 study BBI608 combination temozolomide patient recurrent progressive glioblastoma receive prior bevacizumab therapy .</brief_summary>
	<brief_title>A Study BBI608 Combination With Temozolomide Adult Patients With Recurrent Progressed Glioblastoma</brief_title>
	<detailed_description>In arm A , patient candidate surgical resection receive BBI608 monotherapy prior resection , follow post-operative BBI608 administer combination temozolomide . In arm B , patient candidate surgical resection receive BBI608 administer orally , daily , combination temozolomide . In phase 1/DLT cohort portion study , pharmacokinetics evaluate arm A B. Pharmacodynamics evaluate patient undergo surgical resection .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>Major Eligilbility Criteria 1 . Signed write informed consent must obtain document accord International Conference Harmonisation ( ICH ) local regulatory requirement . 2 . A histologically confirm supratentorial glioblastoma ( GBM ) first recurrence/progression ( except transformation previous low grade glioma ) follow standard frontline therapy , treatment temozolomide ( TMZ ) would acceptable determined Investigator 3 . Previously receive standard frontline GBM treatment include maximal surgical resection follow external beam radiation therapy . 4 . Patients may may candidate repeat surgical resection recurrent/progressed GBM . 5 . Patients must unequivocal evidence tumor recurrence/progression MRI minimum 12 week follow completion chemoradiation radiation therapy . 6 . Patients must measurable nonmeasurable disease response assessment neurooncology ( RANO ) criteria 7 . â‰¥18 year age . 8 . Eastern Oncology Cooperative Group ( ECOG ) performance status 0 1</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>GBM</keyword>
	<keyword>Malignant Glioma</keyword>
</DOC>